Should these interpretations prove valid a two‐pronged treatment approach might be considered that would involve selection of patients with evidence of chronic activation of inflammasomes in their tumor such as high CRP levels and treatment with agents that limit inflammation such as inhibition of circulating IL‐1β and inhibition of NF‐kB by use of BET protein inhibitors. Here, CRP is linked to neoplasm.